Rubella

Generalities
Agent	Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period	14-17 days (range 14-21 days)
Period of transmissibility	- 7 days before rash and 4 days after rash onset - From congenital rubella: infants shed the virus for several months after birth
Reservoir	Humans
Modes of transmission	- Person-to-person: direct contact with droplets - Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine. - Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation	- Febril maculo-papular rash - Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis - Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions	- MOPH circular no 12 (2013): Acquired Rubella - MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms	- Rash reporting form - CRS reporting form - Rash investigation form - CRS investigation form
Data	- Rubella 2021 - Rubella 2020 - Rubella 2019 - Rubella 2018 - Rubella 2017 - Rubella 2016 - Rubella 2015

ATC	Name	B/G	Ingredients	Dosage	Form	Price
R06AX27	ORADUS	G	Desloratadine - 0.5mg/ml	0.5mg/ml	Solution	199,657 L.L
R06AX27	RINA	G	Desloratadine - 0.5mg/ml	0.5mg/ml	Syrup	159,917 L.L
R06AX28	RUPATADINE BIOGARAN	G	Rupatadine - 10mg	10mg	Tablet	341,336 L.L
R06AX29	LABIXTEN	B	Bilastine - 20mg	20mg	Tablet	584,571 L.L
R06AX29	LABIXTEN	B	Bilastine - 2.5mg/ml	2.5mg/ml	Solution	463,626 L.L
R07AA	SURFACTANTE B RICHET	G	Pulmonary surfactant, bovine - 200mg/8ml	200mg/8ml	Suspension	26,568,472 L.L
R07AA	INFASURF	B	Calfactant - 210mg/6ml	35mg/ml	Injectable suspension	40,596,749 L.L
R07AA	INFASURF	B	Calfactant - 105mg/3ml	35mg/ml	Injectable suspension	23,344,161 L.L
R07AA01	SURVANTA	B	Colfosceril palmitate - 200mg/8ml	200mg/8ml	Suspension	36,957,499 L.L
S01AA09	TETRACYCLINE EYE OINTMENT	G	Tetracycline HCl - 1%	1%	Ointment	71,672 L.L
S01AA12	TOBRACIN	G	Tobramycin - 0.3%	0.3%	Drops	322,522 L.L
S01AA12	TOBRASTILL	G	Tobramycin - 0.3%	0.3%	Drops solution	258,018 L.L
S01AA12	TOBRACIN	G	Tobramycin - 0.3%	0.3%	Ointment	280,863 L.L
S01AA13	FUCITHALMIC VISCOUS	B	Fusidic acid - 10mg/g	1%	Drops	373,588 L.L
S01AA13	OPTIFUCIN VISCOUS	G	Fusidic acid - 1%	1%	Drops	208,296 L.L
S01AA23	NETTACIN	B	Netilmicin - 0.3%	0.3%	Drops solution	681,328 L.L
S01AA23	NETTACIN	B	Netilmicin - 0.3%	0.3%	Ointment	593,978 L.L
S01AA26	AZYTER	G	Azithromycin (dihydrate) - 15mg/g	15mg/g	Drops solution	412,560 L.L
S01AD09	VIRGAN	B	Ganciclovir - 1.5mg/g	1.5mg/g	Gel	804,962 L.L
S01AE01	OFLOX	B	Ofloxacin - 3mg/ml	0.3%	Drops solution	366,869 L.L
S01AE01	OFLOX	B	Ofloxacin - 0.3%	0.3%	Drops solution	366,869 L.L
S01AE01	FLOXIGEN	G	Ofloxacin - 3mg/ml	3mg/ml	Drops solution	358,806 L.L
S01AE01	OPTIFLOX	G	Ofloxacin - 3mg/ml	3mg/ml	Drops suspension	143,791 L.L
S01AE01	FLOXEDOL	G	Ofloxacin - 3mg/ml	3mg/ml	Gel	339,992 L.L
S01AE02	NAFLOX	G	Norfloxacin - 3mg/ml	3mg/ml	Drops	370,901 L.L
S01AE03	CILOXAN	B	Ciprofloxacine (HCl) - 3mg/ml	3mg/ml	Drops solution	348,055 L.L
S01AE06	TYMER	G	Gatifloxacin (sesquihydrate) - 3mg/ml	3mg/ml	Drops solution	427,342 L.L
S01AE07	AROX	G	Moxifloxacin (HCl) - 0.5%	0.5%	Drops	423,310 L.L
S01AE07	FORTYMOX	G	Moxifloxacin (HCl) - 0.5%	0.5%	Drops solution	772,709 L.L
S01AE07	IMOX	G	Moxifloxacin (HCl) - 0.5%	0.5%	Drops	464,970 L.L